ESSA Historical Balance Sheet

EPIX Stock

USD 1.68 0.02 1.18%

Trend analysis of ESSA Pharma balance sheet accounts such as Total Current Liabilities of 3 M or Total Stockholder Equity of 154.7 M provides information on ESSA Pharma's total assets, liabilities, and equity, which is the actual value of ESSA Pharma to its prevalent stockholders. By breaking down trends over time using ESSA Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ESSA Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ESSA Pharma is a good buy for the upcoming year.

ESSA Pharma Inventory

133.56 Million

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

About ESSA Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ESSA Pharma at a specified time, usually calculated after every quarter, six months, or one year. ESSA Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ESSA Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ESSA currently owns. An asset can also be divided into two categories, current and non-current.

ESSA Pharma Balance Sheet Chart

At this time, ESSA Pharma's Net Tangible Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 30.8 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 845 K in 2025.

Total Assets Other Current Liab Total Current Liabilities Net Debt Non Current Assets Total Intangible Assets

Add Fundamental

Total Assets

Total assets refers to the total amount of ESSA Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ESSA Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on ESSA Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ESSA Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Most accounts from ESSA Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.At this time, ESSA Pharma's Net Tangible Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 30.8 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 845 K in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	1.4M	773.5K	889.5K	845.0K
Total Assets	149.1M	128.1M	147.3M	154.7M

Other Current Liab Total Assets

ESSA Pharma balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Other Liab	Net Tangible Assets	Other Assets	Long Term Debt	Net Receivables	Inventory	Property Plant Equipment	Property Plant And Equipment Net	Common Stock Shares Outstanding
Total Assets		0.59	0.38	1.0	-0.89	-0.91	0.32	0.88	0.41	0.51	0.93	0.44	0.7	-0.04	1.0	-0.01	0.97	-0.3	0.98	0.66	0.59	-0.15	0.93	0.66	0.75	0.95
Other Current Liab	0.59		0.01	0.59	-0.53	-0.28	-0.12	0.43	0.11	0.35	0.37	0.62	0.0	-0.17	0.6	-0.06	0.41	-0.16	0.46	0.48	0.26	-0.04	0.35	0.54	0.27	0.39
Total Current Liabilities	0.38	0.01		0.35	-0.42	-0.41	0.7	0.43	0.57	0.19	0.44	0.56	0.26	0.72	0.38	0.26	0.38	0.15	0.35	0.3	0.58	0.15	0.32	0.59	0.45	0.31
Total Stockholder Equity	1.0	0.59	0.35		-0.89	-0.91	0.3	0.88	0.39	0.49	0.93	0.41	0.71	-0.09	1.0	-0.02	0.97	-0.32	0.99	0.65	0.58	-0.15	0.94	0.64	0.75	0.96
Net Debt	-0.89	-0.53	-0.42	-0.89		0.8	-0.34	-0.98	-0.42	-0.42	-0.91	-0.44	-0.71	0.01	-0.89	0.0	-0.86	0.26	-0.89	-0.62	-0.55	0.13	-0.8	-0.7	-0.82	-0.84
Retained Earnings	-0.91	-0.28	-0.41	-0.91	0.8		-0.47	-0.82	-0.46	-0.57	-0.87	-0.26	-0.86	-0.05	-0.9	-0.03	-0.97	0.27	-0.95	-0.44	-0.65	0.19	-0.93	-0.54	-0.76	-0.97
Accounts Payable	0.32	-0.12	0.7	0.3	-0.34	-0.47		0.36	0.56	0.52	0.4	0.43	0.42	0.66	0.32	0.24	0.4	0.54	0.35	0.19	0.27	0.18	0.38	0.48	0.57	0.36
Cash	0.88	0.43	0.43	0.88	-0.98	-0.82	0.36		0.44	0.41	0.91	0.4	0.8	0.03	0.88	0.03	0.89	-0.27	0.9	0.56	0.58	-0.14	0.83	0.64	0.87	0.86
Non Current Assets Total	0.41	0.11	0.57	0.39	-0.42	-0.46	0.56	0.44		0.44	0.42	0.33	0.46	0.46	0.41	0.59	0.45	0.05	0.42	0.31	0.42	0.13	0.51	0.19	0.66	0.41
Non Currrent Assets Other	0.51	0.35	0.19	0.49	-0.42	-0.57	0.52	0.41	0.44		0.46	0.35	0.46	0.41	0.51	0.06	0.55	0.31	0.5	0.32	0.43	-0.24	0.51	0.26	0.51	0.54
Cash And Short Term Investments	0.93	0.37	0.44	0.93	-0.91	-0.87	0.4	0.91	0.42	0.46		0.32	0.75	0.02	0.93	0.01	0.92	-0.28	0.94	0.77	0.57	-0.14	0.9	0.62	0.77	0.9
Other Current Assets	0.44	0.62	0.56	0.41	-0.44	-0.26	0.43	0.4	0.33	0.35	0.32		0.08	0.46	0.44	0.12	0.33	0.13	0.33	0.31	0.49	0.32	0.22	0.76	0.44	0.28
Other Stockholder Equity	0.7	0.0	0.26	0.71	-0.71	-0.86	0.42	0.8	0.46	0.46	0.75	0.08		0.03	0.7	0.07	0.84	-0.25	0.81	0.21	0.55	-0.19	0.83	0.31	0.83	0.86
Total Liab	-0.04	-0.17	0.72	-0.09	0.01	-0.05	0.66	0.03	0.46	0.41	0.02	0.46	0.03		-0.04	0.22	-0.01	0.55	-0.07	0.01	0.41	-0.05	-0.04	0.16	0.21	-0.07
Total Current Assets	1.0	0.6	0.38	1.0	-0.89	-0.9	0.32	0.88	0.41	0.51	0.93	0.44	0.7	-0.04		-0.01	0.97	-0.3	0.98	0.66	0.6	-0.16	0.93	0.66	0.75	0.95
Intangible Assets	-0.01	-0.06	0.26	-0.02	0.0	-0.03	0.24	0.03	0.59	0.06	0.01	0.12	0.07	0.22	-0.01		0.02	0.2	0.0	-0.04	0.02	0.17	0.02	0.02	0.12	0.01
Common Stock	0.97	0.41	0.38	0.97	-0.86	-0.97	0.4	0.89	0.45	0.55	0.92	0.33	0.84	-0.01	0.97	0.02		-0.29	0.99	0.55	0.62	-0.17	0.97	0.57	0.81	1.0
Other Liab	-0.3	-0.16	0.15	-0.32	0.26	0.27	0.54	-0.27	0.05	0.31	-0.28	0.13	-0.25	0.55	-0.3	0.2	-0.29		-0.32	-0.17	-0.4	0.01	-0.27	-0.08	-0.07	-0.31
Net Tangible Assets	0.98	0.46	0.35	0.99	-0.89	-0.95	0.35	0.9	0.42	0.5	0.94	0.33	0.81	-0.07	0.98	0.0	0.99	-0.32		0.6	0.59	-0.16	0.97	0.6	0.8	0.99
Other Assets	0.66	0.48	0.3	0.65	-0.62	-0.44	0.19	0.56	0.31	0.32	0.77	0.31	0.21	0.01	0.66	-0.04	0.55	-0.17	0.6		0.28	-0.03	0.57	0.45	0.42	0.5
Long Term Debt	0.59	0.26	0.58	0.58	-0.55	-0.65	0.27	0.58	0.42	0.43	0.57	0.49	0.55	0.41	0.6	0.02	0.62	-0.4	0.59	0.28		-0.25	0.52	0.52	0.48	0.6
Net Receivables	-0.15	-0.04	0.15	-0.15	0.13	0.19	0.18	-0.14	0.13	-0.24	-0.14	0.32	-0.19	-0.05	-0.16	0.17	-0.17	0.01	-0.16	-0.03	-0.25		-0.17	0.17	0.11	-0.19
Inventory	0.93	0.35	0.32	0.94	-0.8	-0.93	0.38	0.83	0.51	0.51	0.9	0.22	0.83	-0.04	0.93	0.02	0.97	-0.27	0.97	0.57	0.52	-0.17		0.41	0.82	0.97
Property Plant Equipment	0.66	0.54	0.59	0.64	-0.7	-0.54	0.48	0.64	0.19	0.26	0.62	0.76	0.31	0.16	0.66	0.02	0.57	-0.08	0.6	0.45	0.52	0.17	0.41		0.47	0.54
Property Plant And Equipment Net	0.75	0.27	0.45	0.75	-0.82	-0.76	0.57	0.87	0.66	0.51	0.77	0.44	0.83	0.21	0.75	0.12	0.81	-0.07	0.8	0.42	0.48	0.11	0.82	0.47		0.79
Common Stock Shares Outstanding	0.95	0.39	0.31	0.96	-0.84	-0.97	0.36	0.86	0.41	0.54	0.9	0.28	0.86	-0.07	0.95	0.01	1.0	-0.31	0.99	0.5	0.6	-0.19	0.97	0.54	0.79

Click cells to compare fundamentals

ESSA Pharma Account Relationship Matchups

ESSA Pharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	198.2M	169.5M	149.1M	128.1M	147.3M	154.7M
Other Current Liab	39.2M	36.4M	1.4M	773.5K	889.5K	845.0K
Total Current Liabilities	3.9M	2.3M	3.5M	3.3M	3.8M	3.0M
Total Stockholder Equity	194.0M	167.1M	145.6M	128.1M	147.3M	154.7M
Net Debt	(137.5M)	(56.9M)	(33.6M)	(103.4M)	(93.0M)	(88.4M)
Retained Earnings	(117.8M)	(152.9M)	(179.5M)	(208.0M)	(187.2M)	(177.8M)
Accounts Payable	1.4M	954.6K	2.0M	2.4M	2.8M	1.5M
Cash	137.8M	57.1M	33.7M	103.7M	119.3M	125.2M
Non Current Assets Total	567.7K	446.0K	325.3K	552.4K	635.3K	401.0K
Cash And Short Term Investments	194.9M	57.1M	148.1M	126.8M	145.8M	153.1M
Other Current Assets	2.2M	1.8M	585.4K	636.5K	731.9K	1.2M
Other Stockholder Equity	36.4M	44.0M	49.0M	130.2M	149.7M	157.2M
Total Liab	4.2M	2.4M	3.5M	3.5M	4.0M	4.5M
Total Current Assets	197.6M	169.5M	148.8M	127.6M	146.7M	154.0M
Common Stock	131.1M	277.4M	278.1M	278.2M	319.9M	335.9M
Net Tangible Assets	49.0M	79.2M	194.0M	167.1M	192.2M	201.8M
Other Assets	198.2M	(446.0K)	115.4M	24.1M	27.7M	30.8M
Net Receivables	489.0K	6.2K	135.1K	163.0K	146.7K	139.3K
Short Term Investments	57.1M	110.2M	114.4M	23.1M	26.5M	32.7M
Liabilities And Stockholders Equity	198.2M	169.5M	149.1M	128.1M	147.3M	75.6M
Short Term Debt	120.7K	133.8K	80.3K	124.1K	111.6K	106.1K
Property Plant And Equipment Net	308.3K	186.5K	68.0K	295.5K	339.8K	356.8K
Common Stock Shares Outstanding	38.5M	44.0M	44.1M	44.3M	50.9M	53.5M
Non Current Liabilities Total	230.6K	77K	(71.0)	205.2K	184.7K	175.5K
Property Plant And Equipment Gross	308.3K	186.5K	68.0K	295.5K	339.8K	356.8K
Capital Lease Obligations	331.0K	210.3K	80.3K	329.3K	378.6K	397.6K
Short Long Term Debt Total	331.0K	209.8K	80.3K	329.3K	296.3K	281.5K
Net Invested Capital	194.0M	167.1M	145.6M	124.6M	143.3M	107.6M
Net Working Capital	193.7M	166.7M	145.3M	124.3M	142.9M	106.0M
Capital Stock	277.4M	278.1M	278.2M	279.9M	321.8M	213.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ESSA Historical Balance Sheet

ESSA Pharma Inventory

133.56 Million

About ESSA Balance Sheet Analysis

ESSA Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Net Debt

Non Current Assets Total

Intangible Assets

ESSA Pharma balance sheet Correlations

ESSA Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ESSA Pharma balance sheet Accounts

Also Currently Popular

Additional Tools for ESSA Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Stockholder Equity
Common Stock Shares Outstanding	+ 1.0	Common Stock
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Net Tangible Assets	+ 0.99	Common Stock

Cash	- 0.98	Net Debt
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Net Tangible Assets	- 0.95	Retained Earnings
Inventory	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.91	Net Debt